Cantargia
Develops antibody therapies targeting IL1RAP for cancer and inflammatory diseases.
CANTA | ST
Overview
Corporate Details
- ISIN(s):
- SE0006371126 (+3 more)
- LEI:
- 549300GKWRT7RXI4VS85
- Country:
- Sweden
- Address:
- Scheelevägen 27, 223 63 Lund
- Website:
- https://cantargia.com/en/
- Sector:
- Manufacturing
Description
Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2021-05-10 15:00 |
Cantargia presenterar nya prekliniska data som visar att antikroppen CAN10 åsta…
|
Swedish | 195.3 KB | ||
| 2021-05-06 16:45 |
Cantargia tar nästa steg i utvecklingen av antikroppen CAN04 med en ny klinisk …
|
Swedish | 205.8 KB | ||
| 2021-05-06 16:45 |
Cantargia advance development of antibody CAN04 by a new clinical trial in trip…
|
English | 195.6 KB | ||
| 2021-04-30 13:00 | Swedish | 8.8 MB | |||
| 2021-04-27 12:45 |
Kallelse till årsstämma i Cantargia AB (publ)
|
Swedish | 281.6 KB | ||
| 2021-04-27 12:45 |
Notice of annual general meeting in Cantargia AB (publ)
|
English | 262.2 KB | ||
| 2021-04-26 15:00 |
Cantargia presenterar nya prekliniska resultat kring antikroppen CAN10 på IMMMU…
|
Swedish | 194.8 KB | ||
| 2021-04-26 15:00 |
Cantargia presents new preclinical data on antibody CAN10 at IMMMUNOLOGY2021
|
English | 188.5 KB | ||
| 2021-03-19 08:30 |
Cantargia reports positive preclinical safety and efficacy results in the CAN10…
|
English | 189.1 KB | ||
| 2021-03-19 08:30 |
Cantargia rapporterar positiva prekliniska resultat kring säkerhet och effekt i…
|
Swedish | 192.5 KB | ||
| 2021-03-10 08:30 |
Cantargia ansöker om start av ny klinisk studie kring antikroppen CAN04 och FOL…
|
Swedish | 198.6 KB | ||
| 2021-03-10 08:30 |
Cantargia submits application to start new clinical trial investigating antibod…
|
English | 193.4 KB | ||
| 2021-02-25 08:30 | Swedish | 528.7 KB | |||
| 2021-02-25 08:30 | English | 531.7 KB | |||
| 2021-02-10 13:30 |
Cantargia reports first patient treated in CANFOUR pancreatic cancer phase IIa …
|
English | 190.8 KB |
Automate Your Workflow. Get a real-time feed of all Cantargia filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cantargia
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cantargia via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-19 | Nedjad Losic | Other | Buy | 21,375 | 33,131.25 SEK |
| 2025-01-02 | Antonius Franciscus Berkien | Other | Other | 21,621 | 39,998.85 SEK |
| 2024-12-20 | Göran Forsberg | Other | Other | 152,206 | 281,581.10 SEK |
| 2024-12-20 | Nedjad Losic | Other | Other | 12,875 | 23,818.75 SEK |
| 2024-12-09 | Antonius Franciscus Berkien | Other | Buy | 3,741 | 6,733.80 SEK |
| 2023-01-19 | Nedjad Losic | Other | Buy | 3,918 | 29,110.74 SEK |
| 2023-01-17 | Göran Forsberg | Other | Buy | 17,000 | 140,250.00 SEK |
| 2023-01-17 | Bengt Jöndell | Other | Buy | 6,500 | 54,665.00 SEK |
| 2022-07-28 | Göran Forsberg | Other | Other | 91,765 | 344,118.75 SEK |
| 2022-07-28 | Thoas Fioretos | Other | Other | 78,400 | 294,000.00 SEK |
Peer Companies
